In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Amgen recently launched a biosimilar version of Regeneron’s eye drug Eylea and could begin marketing a copycat form of ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...